Derma Sciences Inc (DSCI) news stock charts
Derma Sciences Inc (DSCI) Investment Summary:
Derma Sciences, Inc., together with its subsidiaries, engages in the manufacture, marketing, and sale of dermatological related product lines in the United States, Canada, and internationally. Its wound care products include dressings, devices, ointments, and sprays to manage and treat various skin conditions comprising burns, skin tears, abrasions, and incontinence related skin impairment, as well as chronic non-healing skin ulcerations, such as pressure, diabetic and venous ulcers, surgical incisions, and serious burns. The company also offers wound closure and specialty securement devices consisting of wound closure strips, nasal tube fasteners, and various catheter fasteners, as well as provides private label wound care, and wound closure and specialty securement devices. In addition, it offers general purpose and specialized skin care products, including antibacterial skin cleansers, soaps, hair and body washes, lotions, body oil, and moisturizers. The company?s products under the development stage comprise Bioguard Barrier Dressings, a novel antimicrobial infection control product; and DSC127, a novel angiotensin analog, which is in Phase II human trials for use in wound healing and scar reduction. Its customers include various health care agencies and institutions, such as nursing homes, hospitals, home healthcare agencies, physician?s offices, and retail and closed door pharmacies, as well as doctors. Derma Sciences sells its products through direct sales force, distributors, and licensing and distribution agreements. The company was founded in 1984 and is headquartered in Princeton, New Jersey.www.dermasciences.com
165 Employees
Founded in 1984
DERMA SCIENCES INC (DSCI:NASDAQ)
LAST $5.10 USD
CHANGE TODAY -0.68 -11.76%
VOLUME 5.1K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of DERMA SCIENCES INC (DSCI)
|
OPEN
$5.69
|
PREVIOUS CLOSE
$5.78
|
|
|
DAY HIGH
$5.70
|
DAY LOW
$5.07
|
|
|
52 WEEK HIGH
02/3/10 - $9.00
|
52 WEEK LOW
04/27/09 - $1.92
|
|
|
MARKET CAP
29.8M
|
AVERAGE VOLUME 10 D
5.4K
|
|
|
EPS TTM
$-0.32
|
SHARES OUTSTANDING
5.8M
|
|
|
DSCI Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for DERMA SCIENCES INC (DSCI)
Derma Sciences Inc. to Report Q4, 2009 Results on 04/01/2010
03/4/2010
Derma Sciences Inc. announced that they will report Q4, 2009 results on 04/01/2010
Derma Sciences Inc., Q4 2009 Earnings Call, Apr-01-2010
03/4/2010
Derma Sciences Inc., Q4 2009 Earnings Call, Apr-01-2010
Derma Sciences Inc. Announces License Agreement with Comvita New Zealand Ltd
03/1/2010
On February 23, 2010, Derma Sciences Inc. entered into a definitive set of agreements with Comvita New Zealand Ltd., pursuant to which the company received perpetual and exclusive worldwide licensing rights for Medihoney professional wound care and skin products covering distribution and sales to all markets outside of the over the counter market. Pursuant to the License Agreement and related Restraint Agreement, the company will pay to Comvita $2.25 million in U.S. dollars, issue Comvita 400,000 shares of its common stock, issue Comvita 133,333 warrants to purchase its common stock at an exercise price of $5.50 per share, and issue to Comvita 100,000 warrants to purchase its common stock at a price of $6.25 per share. The License Agreement also calls for royalty payments on all sales and additional payments to Comvita if certain Medihoney net sales milestones are achieved over the course of the license. The license rights may be terminated or rendered non-exclusive by Comvita if the company fails to meet certain minimum royalty requirements. In addition to a License Agreement and Restraint Agreement, the company and Comvita also entered into several other related agreements, including a Collaborative Research and Development Agreement, a Medical Honey Supply Agreement, and a Manufacturing Agreement pursuant to which the company will manufacture Medihoney brand OTC products for Comvita.
Derma Sciences Inc financial resources
DSCI Competitors
| Company | Last | Change |
| 3M Co | $81.96 USD | -1.71 |
| Covidien PLC | $51.24 USD | +0.39 |
| Johnson & Johnson | $65.11 USD | +0.05 |
| Medical Action Industries Inc | $13.17 USD | +0.07 |
| Smith & Nephew PLC | 669.50 GBp | -2.50 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | DSCI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.5x |
|
| Price/Book | 1.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.5x |
|
|
DSCI |
||
|
DSCI transactions
| Type Date |
Target |
|
Merger/Acquisition
December 21, 2009 |
Derma Sciences Inc., worldwide licensing rights for Medihoney |
More Recent Financial News About Derma Sciences Inc
Derma Sciences Announces Fourth Quarter and Full Year 2009 Results Conference Call
2010-03-11 07:57:22
Quote: PRINCETON, N.J., March 4Derma Sciences, Inc.NasdaqDSCINews), a specialty medical device/pharmaceutical company focused on advanced wound care, will hold a conference call on April 1, 2010 to discuss the results for the fourth quarter and full year ended December 31, 2009. The conference call is scheduled to begin at 11:00 a.m. Eastern Daylight Time (EDT). Â The results will be released at approximately 9:00 a.m. EDT that same day.To access the conference call, US-based listeners should dial (8...Read article
Derma Sciences Announces Fourth Quarter and Full Year 2009 Results Conference Call
2010-03-05 05:40:43
Quote: PRINCETON, N.J., March 4Derma Sciences, Inc.NasdaqDSCINews), a specialty medical device/pharmaceutical company focused on advanced wound care, will hold a conference call on April 1, 2010 to discuss the results for the fourth quarter and full year ended December 31, 2009. The conference call is scheduled to begin at 11:00 a.m. Eastern Daylight Time (EDT). Â The results will be released at approximately 9:00 a.m. EDT that same day.To access the conference call, US-based listeners should dial (8...Read article
Derma Sciences Announces Full Exercise of Over-Allotment Option and Closing of Public Equity Offering
2010-03-04 09:23:22
Quote: Â Derma Sciences closed its previously announced follow-on equity offering, for a total of 1,117,800 common shares and warrants to purchase 372,600 shares. Â Each share, together with a warrant to purchase one-third of a share, was priced at $5.00. Â The exercise price of the warrants in the offering is $5.50. Â The Company realized net proceeds of $4.7 million from this offering.Proceeds of the offering will be used towards paying Comvita New Zealand for the perpetual worldwide licensi...Read article
Derma completes license deal for Medihoney rights
2010-03-04 09:23:21
Quote: (AP) -- Medical device maker and drug developer Derma Sciences Inc. said Thursday it finalized a deal to license worldwide rights to Medihoney wound and skin care products from Comvita New Zealand Ltd.The company announced the deal Dec. 22.Under the deal, Derma will pay Comvita $2.25 million, issue Comvita 400,000 shares of its common stock, issue Comvita 133,333 warrants to purchase its common stock at an exercise price of $5.50 per share, and issue to Comvita 100,000 warrants to purchase its c...Read article
Derma Sciences Finalizes Licensing Agreement for Worldwide Rights to MEDIHONEY(R)
2010-03-04 09:23:21
Quote: (Comvita) of Paengaroa, New Zealand, giving Derma Sciences perpetual and exclusive worldwide licensing rights for MEDIHONEY® professional wound care and skin products covering distribution and sales to all markets outside of the over the counter (OTC) market.   In addition to a License Agreement and Restraint Agreement, Derma Sciences and Comvita also entered into several other related agreements, including a Collaborative Research and Development Agreement, a Medical Honey Supply Agre...Read article
Derma Sciences Finalizes Licensing Agreement for Worldwide Rights to MEDIHONEY(R)
2010-02-26 09:59:07
Quote: (Comvita) of Paengaroa, New Zealand, giving Derma Sciences perpetual and exclusive worldwide licensing rights for MEDIHONEY® professional wound care and skin products covering distribution and sales to all markets outside of the over the counter (OTC) market.   In addition to a License Agreement and Restraint Agreement, Derma Sciences and Comvita also entered into several other related agreements, including a Collaborative Research and Development Agreement, a Medical Honey Supply Agre...Read article
Derma completes license deal for Medihoney rights
2010-02-26 09:59:06
Quote: (AP) -- Medical device maker and drug developer Derma Sciences Inc. said Thursday it finalized a deal to license worldwide rights to Medihoney wound and skin care products from Comvita New Zealand Ltd.The company announced the deal Dec. 22.Under the deal, Derma will pay Comvita $2.25 million, issue Comvita 400,000 shares of its common stock, issue Comvita 133,333 warrants to purchase its common stock at an exercise price of $5.50 per share, and issue to Comvita 100,000 warrants to purchase its c...Read article
DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal
2010-02-25 05:33:54
Quote: Item 1.01 Entry into a Material Definitive Agreement
On February 18, 2010, Derma Sciences, Inc. (the "Registrant") entered into a
nominating agreement (the "Nominating Agreement") with Comvita New Zealand
Limited ("Comvita"). The Nominating Agreement provides that so long as Comvita
owns at least 10% of the outstanding common stock of the Registrant, the
Registrant's board of directors will nominate, in connection with each
shareholder solicitation relating to the ...Read article
Derma Sciences Announces Full Exercise of Over-Allotment Option and Closing of Public Equity Offering
2010-02-24 10:49:11
Quote: Â Derma Sciences closed its previously announced follow-on equity offering, for a total of 1,117,800 common shares and warrants to purchase 372,600 shares. Â Each share, together with a warrant to purchase one-third of a share, was priced at $5.00. Â The exercise price of the warrants in the offering is $5.50. Â The Company realized net proceeds of $4.7 million from this offering.Proceeds of the offering will be used towards paying Comvita New Zealand for the perpetual worldwide licensi...Read article
Derma Sciences, Inc. to List Its Common Stock on NASDAQ
2010-02-23 04:13:14
Quote: 9 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCID), a specialty medical device/pharmaceutical company focused on advanced wound care, will list its common stock on the NASDAQ Capital Market effective February 10, 2010 under the ticker symbol "DSCI"."The NASDAQ listing represents a significant step for Derma Sciences that will provide increased visibility and should result in improved liquidity for our shares," said CEO Ed Quilty.About Derma Sciences, Inc.Derma Sciences ...Read article
Derma Sciences Featured on NJN News and WNET 13
2010-02-23 04:13:13
Quote:  Kessler reported how Derma Sciences' MEDIHONEY®, globally the most prescribed medical honey-based dressing for wounds and burns, helps to kick-start stalled wounds and decrease complications associated with diabetic foot ulcers.  MEDIHONEY® products are manufactured and marketed by Derma Sciences, which will close on the worldwide rights to the products in the next few days. Wound care specialists, including those at Hunterdon Wound Healing Center in Flemington, NJ, are using MEDIHO...Read article
Derma Sciences Announces Pricing of Follow-on Offering
2010-02-23 04:13:13
Quote: Alternatively, a copy of the prospectus related to this offering may be obtained from Rodman & Renshaw, LLC, Prospectus Department, 1251 Avenue of the Americas, New York, NYinfo@rodm.com.About Derma SciencesDerma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dre...Read article
DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen
2010-02-23 04:13:12
Quote: Item 1.01 Entry into a Material Definitive Agreement
On February 16, 2010, Derma Sciences, Inc. (the "Registrant") entered into an
underwriting agreement (the "Underwriting Agreement") with Rodman & Renshaw, LLC
(the "Underwriter") pursuant to which the Registrant agreed to sell 972,000
shares of its common stock, $0.01 par value per share (the "Common Stock") and
warrants to purchase an additional 324,000 shares of common stock (the
"Warrants&qu...Read article
Derma Sciences, Inc. to List Its Common Stock on NASDAQ
2010-02-22 01:18:09
Quote: 9 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCID), a specialty medical device/pharmaceutical company focused on advanced wound care, will list its common stock on the NASDAQ Capital Market effective February 10, 2010 under the ticker symbol "DSCI"."The NASDAQ listing represents a significant step for Derma Sciences that will provide increased visibility and should result in improved liquidity for our shares," said CEO Ed Quilty.About Derma Sciences, Inc.Derma Sciences ...Read article
DERMA SCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2010-02-22 01:18:09
Quote: Item 8.01 Other Events
On January 28, 2010 the board of directors of Derma Sciences, Inc. (the
"Registrant"), pursuant to the authority granted to it by the Registrant's
shareholders at a special meeting thereof held November 23, 2009, voted to amend
the Registrant's articles of incorporation in order to: (i) effect a reverse
split of the Registrant's common and preferred shares in the ratio of
one-for-eight, and (ii) effect a reduction of authorized common and preferred
shares by a l...Read article
DERMA SCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2010-02-22 01:18:09
Quote: Item 8.01 Other Events
On January 28, 2010 the board of directors of Derma Sciences, Inc. (the
"Registrant"), pursuant to the authority granted to it by the Registrant's
shareholders at a special meeting thereof held November 23, 2009, voted to amend
the Registrant's articles of incorporation in order to: (i) effect a reverse
split of the Registrant's common and preferred shares in the ratio of
one-for-eight, and (ii) effect a reduction of authorized common and preferred
shares by a l...Read article
Derma Sciences Featured on NJN News and WNET 13
2010-02-22 01:18:08
Quote:  Kessler reported how Derma Sciences' MEDIHONEY®, globally the most prescribed medical honey-based dressing for wounds and burns, helps to kick-start stalled wounds and decrease complications associated with diabetic foot ulcers.  MEDIHONEY® products are manufactured and marketed by Derma Sciences, which will close on the worldwide rights to the products in the next few days. Wound care specialists, including those at Hunterdon Wound Healing Center in Flemington, NJ, are using MEDIHO...Read article
DERMA SCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2010-02-22 01:18:08
Quote: DERMA SCIENCES, INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
DERMA SCIENCES, INC.
11-Feb-2010Other Events, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
...Read article
Derma Sciences' Shareholders Approve Reverse Stock Split
2010-02-01 02:43:42
Quote: DSCINews) a specialty medical device/pharmaceutical company focused on advanced wound care, announced today that its shareholders granted Derma Sciences' Board of Directors authority to implement a reverse stock split in the range of between 1-to-5 and 1-to-10.Ed Quilty, Chairman and CEO of Derma Sciences, said, "We have filed an application to list our stock on the NASDAQ Global Market or NASDAQ Capital Market.The reverse stock split our stockholders approved at today's special meeting will ena...Read article
Derma Sciences Files S-1 Registration Statement
2010-02-01 02:43:42
Quote: DSCINewsRODMNews) will act as sole book-running manager for the transaction.Along with the raise, Derma has applied to list its shares on the NASDAQ under the symbol "DSCI."To meet the exchange's price requirement, Derma will hold a special shareholders' meeting on November 23, 2009 to vote on a reverse split of the Company's stock.Derma Sciences will use the net offering proceeds to complete the purchase of the world-wide licensing rights to Medihoney, retire debt, purchase cost savings-related...Read article
Would you like to leave a comment about Derma Sciences Inc DSCI
Find out what social network information about Derma Sciences Inc are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Derma Sciences Inc's Stock there is more great penny stock and market information at Realpennies